As PGx Matures, US Medical Schools Struggle to Keep Students Informed | GenomeWeb

Drug makers and pharmacogenomics researchers anxious that physicians entering practice today will be ill-equipped to embrace personalized medicine may have reason to worry.

Some medical schools, aware that pharmacogenomics is caught in a limbo between its potential real-world application and hype, are encouraging their students to probe the new discipline delicately. But instead of committing to traditional textbooks and core curricula, most medical schools instead are relying on the age-old tool of learning by osmosis — that is, learning by observing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.